RecruitingNot ApplicableNCT04416165
Comparison of FDG and FAPI in Patients With Various Types of Cancer
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
3,000 participants
Start Date
Oct 20, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria1
- (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria1
- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT
Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04416165
Related Trials
Standardized Nutritional Management of Pediatric Patients With Solid Tumors
NCT067302041 location
TumorGlow Intraoperative Molecular Imaging (IMI)
NCT047238101 location
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT074332839 locations
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
NCT073480421 location
Immune Profiling for Cancer Immunotherapy Response
NCT061160321 location